Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. Dezember 2025 09:15 ET | Quelle: Longeveron

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Longeveron granted Canadian patent for method of using stem cells to treat patients with aging-related frailty and also for the treatment of NIDCM.
12. November 2025 09:05 ET | Quelle: Longeveron

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Longeveron issued US patent for method of treating aging-related frailty in patients with inflammaging using its proprietary stem cell therapy.
24. August 2021 07:32 ET | Quelle: HCW Biologics, Inc

HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctional Cancer Immunotherapeutic

Lead Drug Candidate Engineered Using Tissue FactOr-Based FusIon (TOBI™) Platform Preclinical Data Demonstrated HCW9218 Antitumor Activity as Single-Agent Monotherapy and as an Adjunct to Enhance...
17. August 2021 07:32 ET | Quelle: HCW Biologics, Inc

HCW Biologics’ Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein (TOBI™) Discovery Platform

TOBI™ Discovery Platform Creates GMP-Scale Heteromeric Fusion Protein Complexes (HFPCs) That Solve Issues with Multi-Signal Receptor Engagement on Immune Cells MIRAMAR, Fla., Aug. 17, 2021 (GLOBE...
13. August 2021 07:10 ET | Quelle: HCW Biologics, Inc

HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights

MIRAMAR, Fla., Aug. 13, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel...
22. Juli 2021 16:05 ET | Quelle: HCW Biologics, Inc

HCW Biologics Inc. Announces Closing of $56.0 Million Initial Public Offering

MIRAMAR, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing...
19. Juli 2021 18:39 ET | Quelle: HCW Biologics, Inc

HCW Biologics Inc. Announces Pricing of $56.0 Million Initial Public Offering

MIRAMAR, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing...